Upexi, Inc. Q1 FY2023 Earnings Call
· Earnings call transcript and AI-powered summary
- Quarter End: September 30, 2022
- Revenue: $11.6 million, up 199% year-over-year (YoY) from $3.9 million
- Gross Profit: $6 million, up $3.4 million YoY
- Gross Margin: 52%, down from prior period due to increased distributor sales and discounts
- Operating Expenses: $9 million, up 159% from $3.5 million YoY
- Net Loss from Continuing Operations: $2.7 million vs. net income of $511,000 YoY
- Cash & Equivalents: $3.3 million
- Stockholder’s Equity: $27 million
- Outstanding Shares: 17,960,748 (as of Nov 11, 2022)
- FY2023 Revenue Estimate: $100 million baseline (calendar year)
Business Context & Updates
- Vertically integrated brand owner focusing on health, wellness, pet, beauty, and toy markets.
- Significant shift in focus post-sale of CBD assets ($23.5 million sale), reallocating into higher margin, high-growth sectors.
- Major acquisitions contributing to revenue growth:
- Cygnet Online (1,200+ SKUs in OTC health & wellness)
- VitaMedica (triple-digit YoY growth, strong Amazon performance)
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional